Abstract
Since its identification in late 2019 the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) In Wuhan, China, by the World Health Organization (WHO), which cause the coronavirus disease 2019, it is rapidly spreading, resulting in the global pandemic. As of 19 December 2022, more than 64 million confirmed cases and 6,645,812 deaths have been reported across the world. Over time, the SARS-CoV-2 acquired genetic mutations resulting in multiple types of SARS-CoV-2 variants and subvariants that have been confirmed. The Omicron (B.1.1.529) variant was identified later in November 2021, with enhanced immune escape and was followed with various sublineages due to mutations in the spike protein of the SARS-CoV-2. However, rapid resurge in COVID-19 reports by Omicron subvariant BF.7(BA.2.75.2) in China and other countries, alarming global threat. The present systematic review was conducted using “Omicron” AND “BA.5.2.1.7” OR “BF.7” in Pub Med, Google Scholar and MedRXiv database and grey literature from the authentic database and websites. We have identified a total of 14 published studies. We have reviewed all the eligible available studies to understand the viral mutations, factors associated with increase in the reports of COVID-19 cases in china and across the world and to evaluate the effectiveness of vaccination and monoclonal antibodies against BF.7 variant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
none to declare
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: csanten7{at}gmail.com
Email: krishnachaitanya.amerneni{at}med.wmich.edu
Email: mohanakrishna.ghanta{at}gmail.com
Email: pad.mythili{at}gmail.com
email: madhubhargavi196{at}gmail.com
email: madhu.adusumilli3{at}gmail.com
Email: sophia.dr{at}gmail.com
Email: madhavrao.pharm{at}aiimsmangalagiri.edu.in
Email: neolog.raj{at}gmail.com
Email: bhawnaajmer001{at}gmail.com
Prior publication: Nil
Sources of Support: Nil
Conflicts of interest: Nil
Read and approved by all authors: Yes.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos